Mycophenolate mofetil for AIHA

Overview
Mycophenolate mofetil is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to prevent rejection in organ transplant recipients. Mycophenolate mofetil is sometimes prescribed off-label to treat autoimmune hemolytic anemia (AIHA). Mycophenolate mofetil is sold under the brand name CellCept.

Mycophenolate mofetil is an immunosuppressant. Mycophenolate mofetil is believed to work by inhibiting the growth of T cells and B cells, which contribute to inflammation in autoimmune conditions such as AIHA.

How do I take it?
Mycophenolate mofetil comes in capsule, tablet, oral suspension, and intravenous injectable forms.

Side effects
According to the FDA, common side effects for mycophenolate mofetil include pain, fever, headache, infections, low blood cell count, hypertension, swelling, diarrhea, constipation, and nausea and vomiting.

Rare but serious side effects listed for mycophenolate mofetil include severe infections, birth defects, and increased risk of certain types of cancer.

For more details about this treatment, visit:

Mycophenolate Mofetil — Drugs.com
http://www.drugs.com/pro/mycophenolate-mofetil....

Mycophenolate Mofetil for the Treatment of Refractory Auto-immune Haemolytic Anaemia and Auto-immune Thrombocytopenia Purpura — British Journal of Haematology
https://onlinelibrary.wiley.com/doi/full/10.104...